The recently discovered proteasome inhibitor PS-341 (bortezomib (Velcade®)) has been associated with decreased production of bcl-2, inhibition of nuclear transcription factor κB (NFκB), and prevention of acquired resistance to chemotherapy in prostate cancer experimental systems [287]. This evidence concerns the gene BCL2 and prostate cancer.